Clearside Biomedical Announces License Agreement with Arctic Vision for XIPERE™ (triamcinolone acetonide suprachoroidal injectable suspension) in Greater China and South Korea
– Arctic Vision to Lead Expansion of Novel Approach to Treating Macular Edema Associated with Uveitis in
– Clearside Eligible to Receive Upfront and Milestone Payments and Royalties on Product Sales –
– Increasing Global Awareness of Innovative Suprachoroidal Injection Platform –
XIPERE is a proprietary suspension of the corticosteroid triamcinolone acetonide formulated for suprachoroidal administration via Clearside’s proprietary SCS Microinjector™ that is being investigated as a targeted treatment of macular edema associated with uveitis.
“This licensing agreement further enables Clearside to expand the commercial opportunity for XIPERE in an attractive geographic market,” said George Lasezkay, Pharm.D., J.D., President and CEO,
“We are excited to enter into this partnership with Clearside and we look forward to working together to bring this novel therapy to patients and healthcare providers in
Under the terms of the agreement, Clearside may receive up to a total of
About XIPERE™ (triamcinolone acetonide suprachoroidal injectable suspension)
XIPERE™ (triamcinolone acetonide suprachoroidal injectable suspension), formerly known as CLS-TA, is a proprietary suspension of the corticosteroid triamcinolone acetonide formulated for administration to the back of the eye for the treatment of macular edema associated with uveitis. Clearside’s patented technology is designed to deliver drug to the suprachoroidal space located between the choroid and the outer protective layer of the eye, known as the sclera. Suprachoroidal injection enables the rapid and adequate dispersion of medicine to the back of the eye, offering the potential for the medicine to act longer and minimize harm to the surrounding healthy parts of the eye. Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc., has the exclusive license for the commercialization and development of XIPERE in
About Arctic Vision
Arctic Vision is a leading specialty ophthalmology company in
Cautionary Note Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe”, “expect”, “may”, “plan”, “potential”, “will”, and similar expressions, and are based on Clearside’s current beliefs and expectations. These forward-looking statements include statements regarding XIPERE’s commercial potential and Arctic Vision’s ability to successfully launch XIPERE in Greater China (mainland
Investor and Media Contacts:
Source: Clearside Biomedical, Inc.